Do you know what BPC‑157 is? This cryptically named peptide is, according to its proponents, a miracle cure for all sorts of illnesses and injuries. Tom Bartlett remains firmly in the skeptical camp as he investigates exactly what research backs up the BPC‑157 claims. Almost all the studies prove to have a link to Croatian pharmacologist Predrag Sikirić—who is all too happy to meet Bartlett and exalt BPC‑157. But once you know what this is, the question remains: Would you take it?

Amid the sellers of red-light panels and blue-light glasses at Beyond, I stumbled on a company marketing a drinkable version of BPC‑157. Its giveaway sticker read We Prefer Oral Peptides, with the word peptides in much smaller letters because haha sex. The representative behind the counter referred to BPC‑157 as “the soccer mom’s peptide” and nonchalantly squirted some from what was essentially a hand-soap dispenser into a tiny plastic cup, then held it out to me. I hesitated, and the peptide hung in the air, unclaimed. “Are you afraid of it?” he asked. The not-so-subtle subtext was that I shouldn’t be, that taking BPC‑157 was equivalent to trying the dissolvable herbal-tea strips a few tables down or giving the giant quartz bowl a whirl. For the record: We were in a hotel hallway and I was being encouraged—dared, really—to try a drug that isn’t FDA-approved, is prohibited by the World Anti-Doping Agency for athletes’ use, and allegedly works throughout the body via some mysterious mechanism that is not entirely predictable. I was being offered an unspecified dose, although I wouldn’t know what dose would be appropriate, because there are no agreed-upon dosing guidelines. I declined the peptide. The representative shrugged and drank it himself.

• Strauss Zelnick, the CEO of Take-Two Interactive, said he prefers working out to playing video games.
• He is a longevity buff, deep into fitness and anti-aging habits.
• In a candid conversation with Business Insider, he said skip the peptides, and try these 7 things instead.

Media mogul Strauss Zelnick spends his days hyper-focused on making the most creative, innovative, best video games in the world.

As the CEO and Chairman of video game-maker Take-Two Interactive, he's readying to release Grand Theft Auto 6 next month.

At home though, he doesn't play games. He prefers to spend his time working out and staying healthy for a long time.

At Business Insider's "The Long Play" event on Thursday, Zelnick said his formula for healthy aging is both simple and effective.

While he calls biohacker Bryan Johnson, the man behind the "Don't Die" movement, a friend, he said trying to live forever is a pretty silly strategy.

"There's almost no evidence that anything anyone is doing will increase your lifespan," he told Business Insider's Senior Leadership & Workplace Correspondent, Sarah Needleman. "How many of us really want to increase our lifespan from like 96 to 101? Look, that is not on my bucket list, thank you very much."

Instead, Zelnick, who wrote a book on "Becoming Ageless" in 2018, focuses on the same core behaviors for "taking care of yourself" that longevity experts around the world swear by for maintaining health and happiness for the long haul.

1: Do not smoke

"Smoking is the factor most highly correlated with a short, unhealthy, and frankly, unhappy life," Zelnick said. "Don't smoke."

2: Don't abuse alcohol and drugs

These lead to "a bad old age, or no old age," he said.

3: Get some exercise

Zelnick said: "You don't have to do what I do," with 6 a.m. wakeup calls for group training sessions, or twice-a-day workouts.

"I do what I do because I love it, it's my passion," he said. "If you walk 30 minutes a day, four or five days a week — just walk — you're like 80% of the way there."

4: Eat a "responsible" diet

Zelnick says he doesn't have an "insanely healthy diet," but he tries to maintain some balance. "I eat a lot of vegetables and salads and protein — I also like sweets, and I do eat carbs."

5: Sleep at least 7 hours a day

Zelnick says he treats this as a non-negotiable for his business.

"If you're getting less than six hours, you're making bad decisions," he said.

6: Have "some kind of emotional or spiritual life"

Longevity experts stress this is key for mental health, and establishing a sense of purpose in the world.

7: Find community

Zelnick said it's critical to get support from "people who love you."

8: Skip overhyped health hacks

Zelnick says don't waste your time with all the overhyped, unproven health hacks.

"All the other stuff, like, peptides? A: No," he said. "We have an FDA for a reason. Don't take something that is not double-blind tested."

And, he said, be careful with some of the internet's most famous longevity gurus. He name-checked controversial Harvard professor David Sinclair, who has made bold promises about the anti-aging effects of unproven supplements, including resveratrol, a plant polyphenol found in grapes and red wine, and NMN, which is a precursor to NAD, the vital coenzyme that's in every cell of our body.

"A medical doctor actually is a degree: M-D, an MD degree," Zelnick said. "Not a David Sinclair degree, he is not actually a doctor."

A plan to give people in the United States easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with its development.

The Department of Health and Human Services (HHS) will allow compounding pharmacies to manufacture and sell peptides that have not yet been added to the list of approved substances, advancing access to those championed by the “Make America Healthy Again” (MAHA) agenda. The HHS stated in a notice that it would be practicing enforcement discretion…

The Department of Health and Human Services (HHS) will allow compounding pharmacies to manufacture and sell peptides that have not yet been added to the list of approved substances, advancing access to those championed by the “Make America Healthy Again” (MAHA) agenda. The HHS stated in a notice that it would be practicing enforcement discretion…

In a unilateral declaration by the health secretary, several injections promoted by online influencers will become widely available. The F.D.A. had advised against the move.

© Almaas Masood/Reuters

• Eli Lilly is developing a more potent weight-loss drug called retatrutide.
• In the first head-to-head trial versus Ozempic, retatrutide takers lost roughly twice as much weight.
• Retatrutide is not FDA-approved yet, but some peptide sellers are skirting the law.

Gym bros call it "reta." Eli Lilly is calling it the winner.

On Wednesday, the pharmaceutical giant announced the results of the first clinical trial pitting Ozempic against its newest, most powerful, and yet-to-be-approved next-generation injectable medication for obesity and diabetes: retatrutide.

Retatrutide won — and it wasn't even close. Type 2 diabetes patients on the highest dose of Ozempic (2 mg) lost an average of 21 pounds over a period of about a year and a half on the drug. Those on retatrutide lost an average of 44 pounds (9 mg) to 47 pounds (12 mg) during that same time. Patients also saw steeper reductions in their A1C, a key marker of blood sugar control (2.2% vs 1.8%).

"We believe retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity and related cardiometabolic conditions," Eli Lilly's Kenneth Custer, the president of Lilly Cardiometabolic, said in a release.

They're calling it 'King Kong'

Ozempic (from Novo Nordisk) was the very first medication of its kind — a novel peptide that mimics one gut hormone, called GLP-1.

Several years later, Mounjaro (from Eli Lilly) was approved, mimicking two hormones, GLP-1 and GIP, and delivering stronger results.

Insiders are calling Eli Lilly's retatrutide the "triple G" or "King Kong" for weight loss because it mimics three hormones: GLP-1, GIP, and a third peptide hormone called glucagon, which helps break down stored fat into energy. Some say it could rival bariatric surgery in clinical results in terms of weight loss.

Eli Lilly is expected to submit retatrutide to the US Food and Drug Administration for approval in early 2027. If all goes well, it could be available sometime next year, for conditions including obesity, obesity-related sleep apnea, and knee osteoarthritis.

In this clinical trial, side effect profiles were generally similar between patients taking Ozempic and retatrutide, but slightly more patients on retatrutide reported diarrhea, while constipation was slightly more common among Ozempic-takers. People on retatrutide also had slightly higher rates of a rare side effect called dysesthesia, triggering tingling, skin-on-fire type sensations.

The clinical trial results have not yet been peer-reviewed or published in a medical journal, but were released as the company prepares to announce its quarterly earnings on Thursday.

Knock-off reta is already booming on the black market

The drug, which is still in clinical trials, has attracted copycat peptide sellers shipping powders labeled "reta" from overseas, stoking a gray market of do-it-yourself injections. Bodybuilders say it helps shred fat and reduce appetite, with fewer side effects than other injectable weight-loss pens.

But nobody really knows exactly what they are taking, though their results seem to roughly mirror what happens when people take the real thing in clinical trials.

In an unusual move, Eli Lilly addressed the pre-approval black-market hype in their release announcing the latest results.

"Retatrutide is an investigational molecule that has not been approved by FDA or any regulatory organization anywhere in the world," the company said in a statement. "Anyone purporting to sell retatrutide to consumers is breaking the law."